Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 4, 2026, with detailed results in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 U.S. net product sales rose to $161.4M from $94.8M, led by FILSPARI sales of $141.1M, up 96% year-over-year
- FSGS launch and IgAN growth generated 2,012 new patient start forms, supporting continued FILSPARI demand expansion
- GAAP net loss widened to $34.8M, or $0.37 per share, including a $40.0M inducement expense tied to 2029 convertible-note repurchases
- Cash, equivalents, and marketable securities totaled $489.2M after $158M net convertible-note proceeds and a $112.5M civorebrutinib upfront payment
- Civorebrutinib expands the pipeline across multiple immune-mediated kidney diseases, while HARMONY topline data remain expected in 2H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.